Investor Alert



1:46 a.m. Dec. 3, 2021 - By Tomi Kilgore
Recently IPO'd Dole reports profit and revenue growth, in face of inflation and supply chain headwindsShares of Dole PLC were indicated up nearly 1% in premarket trading Friday, after the fresh fruit and vegetables company, , reported a rise in third-quarter profit and revenue, in the face of inflationary pressures and supply chain congestion and labor shortages. Pro-forma net income rose to $29.9 million, or 31 cents a share, from $18.6 million, or 20 cents a share, in the year-ago period. Revenue rose 0.3% to $2.32 billion, while cost of sales grew 0.7% to $2.18 billion. FactSet did not have consensus estimates for earnings or revenue. Fresh fruit revenue rose 0.8% to $676.8 million, as lower volume of bananas in North American and lower pricing of bananas in Europe and pineapples in North America offset higher banana pricing in North American and volume growth in pineapples. Fresh vegetables revenue increased 1.0% to $323.8 million as higher pricing in its value-added salads business offset lower volumes. For 2021, the company is expecting revenue of $9.2 billion to $9.4 billion. The stock has tumbled 16.7% over the past three months while the S&P 500 has gained 0.9%.
2:32 a.m. Nov. 16, 2021 - By Ciara Linnane
Moderna says EU and EEA to donate more than 70 million COVID-19 vaccine does to Covax program in 2021Moderna Inc. said Tuesday the European Union and European Economic Area countries have agreed to donate more than 70 million doses of the company's COVID-19 vaccine to the Covax program in 2021, helping the World Health Organization-backed organization deliver vaccines to low-income countries. The initiative was led by France, Sweden and Norway and includes an initial donation of 15 million doses from France and 40 million from Germany. Covax is co-led by Gavi, the Vaccine Alliance (Gavi), the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO and seeks to ensure vaccine supply for all countries, regardless of income levels. Moderna shares were down 1.1% premarket but have gained 125% in the year to date, while the SPDR S&P Biotech ETF has fallen 12% and the S&p 500 has gained 25%.
3:32 a.m. May 19, 2021 - By Tonya Garcia
TJX earnings beat expectations though COVID-related store closures still weighTJX Cos. reported fiscal first-quarter net income of $533.9 million, or 44 cents per share, after a loss of $887.5 million, or 74 cents per share, last year. Sales of $10.09 billion were up from $4.41 billion last year. The FactSet consensus was for EPS of 31 cents and sales of $8.61 billion. All U.S. stores were operating during the quarter, but the off-price retailer still had locations shuttered in other regions for 14% of the days in the first quarter due to COVID-19. European locations were closed for 76% of the days, and Canadian stores were closed 25%. Still, it was a marked improvement from last year when stores around the world were shut for half the days. Three hundred locations around the globe are currently temporarily closed. Open-only comp store sales were up 16% in the most recent quarter. Open-only comp store sales only account for the days when stores were open during fiscal Q1 2022 and the same period in fiscal 2020. Due to the continued uncertainty of the pandemic, TJX did not provide guidance. However, the company said open-only comp store sales at the start of the second quarter have been similar to the first quarter. The TJX lineup includes TJ Maxx and HomeGoods. TJX stock slipped 0.9% in Wednesday premarket trading, but is up 4.2% for the year to date. The S&P 500 index has gained 9.9% for 2021 so far.
3:06 a.m. Feb. 24, 2021 - By Tonya Garcia
TJX profit and sales take a hit after COVID-19-related store closuresTJX Cos. shares fell 2.7% in Wednesday premarket trading after the off-price retailer reported fourth-quarter earnings and sales that missed expectations. Net income totaled $325.5 million, or 27 cents per share, down from $984.8 million, or 81 cents per share last year. Sales totaled $10.94 billion, down from $12.21 billion last year. The FactSet consensus was for EPS of 62 cents and sales of $11.48 billion. TJX, whose portfolio of stores includes TJ Maxx and Marshalls, says Q4 sales took a $950 million to $1.05 billion hit due to COVID-19-related store closures in Canada and Europe. Earnings per share were reduced by 18 cents to 21 cents. Stores in Canada were closed for about 32% of the fourth quarter, and European stores were closed 63%. There are currently about 690 stores closed due to the pandemic, most in Europe where the company expects stores to be closed for 67% of the first quarter. Due to the ongoing uncertainty from the coronavirus, TJX did not provide financial guidance. TJX stock has gained 13.7% over the past year while the S&P 500 index is up 20.3% for the period.
2:48 a.m. Feb. 19, 2021 - By Jaimy Lee
J&J submits application for its COVID-19 vaccine to the WHOShares of Johnson & Johnson gained 0.4% in premarket trading on Friday after the company said it had submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. Obtaining an emergency-use listing from the WHO allows J&J's vaccine candidate to be made available through Covax, a global consortium supplying COVID-19 vaccines to lower-income countries. J&J's vaccine, which has not yet been authorized for use in the U.S., is set to be reviewed by a group of vaccine experts next week as part of the Food and Drug Administration's regulatory process. The company also submitted a regulatory application for its coronavirus vaccine in the European Union on Feb. 15. J&J's stock is up 11.3% over the past year, while the S&P 500 is up 16.3%.
3:20 a.m. Feb. 11, 2021 - By Tomi Kilgore
Kellogg stock slips after profit and sales miss, but guidance is for surprise earnings growth this yearShares of Kellogg Co. slipped 0.2% in premarket trading Thursday, after the cereal and snacks company reported fourth-quarter profit and sales that missed expectations, but pointed toward surprise growth in full-year earnings. Net income for the quarter to Jan. 2 rose to $385 million, or 59 cents a share, from $360 million, or 42 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share slipped to 86 cents from 91 cents, but below the FactSet consensus of 89 cents. Sales rose 7.5% to $3.46 billion, but came up shy of the FactSet consensus of $3.51 billion. Europe showed the strongest growth with sales rising 15%, led by cereal. North America sales rose 8%, as strength in retail channel sales helped offset weakness in away-from-home channels. For 2021, the company expects adjusted EPS to rise about 1%, while the current FactSet EPS consensus of $3.96 implies a 0.8% decline. The stock has dropped 11.4% over the past three months through Wednesday, while the SPDR Consumer Staples Select Sector ETF has eased 1.4% and the S&P 500 has gained 9.4%.
2:16 a.m. Feb. 11, 2021 - By Tomi Kilgore
Molson Coors stock sinks after profit, revenue miss as Europe weakness weighsShares of Molson Coors Beverage Co. sank 3.1% in premarket trading Thursday, after the beer brewer reported a fourth-quarter adjusted profit and sales that missed expectations, weighed by weakness in Europe amid further on-premise restrictions in the U.K. amid a surge in COVID-19 cases. On a net basis, the company swung to a net loss of $1.37 billion, or $6.32 a share, from income of $163.7 million, or 75 cents a share, in the year-ago period. Excluding nonrecurring items, such as a $1.5 billion Europe goodwill impairment charge, adjusted earnings per share declined to 40 cents from $1.02, missing the FactSet consensus of 77 cents. Sales fell 7.7% to $2.29 billion, below the FactSet consensus of $2.41 billion, as North America sales slipped 0.8% while Europe sales tumbled 37.2%. For 2021, the company expects sales growth in the mid-single digit percentage range, when excluding current impacts. "While uncertainty and on-premise challenges remain, particularly in Europe, we anticipate 2021 to be a year of both top-line growth, as we begin to benefit from the early successes of our revitalization plan, and of investment, as we continue to drive toward long-term revenue and underlying EBITDA growth," said Chief Financial Officer Tracey Joubert. The stock has run up 15.6% over the past three months through Wednesday, while the S&P 500 has gained 9.4%.
1:16 a.m. Feb. 11, 2021 - By Tomi Kilgore
PepsiCo stock edges up after profit and revenue top forecasts, dividend raised by 5%Shares of PepsiCo Inc. edged up 0.1% in premarket trading Thursday, after the beverage and snack company reported fourth-quarter profit that topped expectations, revenue that rose above forecasts and raised its dividend. Net income rose to $1.85 billion, or $1.33 a share, from $1.77 billion, or $1.26 a share, in the year-ago period. Excluding nonrecurring items, core earnings per share grew to $1.47 from $1.45, above the FactSet consensus of $1.46. Revenue increased 8.8% to $22.46 billion, beating the FactSet consensus of $21.80 billion. In North America, Frito-Lay revenue rose 5.7% to $5.44 billion, just shy of the FactSet consensus of $5.48 billion; Quaker Foods revenue increased 8.3% to $836 million, above expectations of $808.4 million; and PepsiCo Beverages revenue grew 8.6% to $6.79 billion, beating forecasts of $6.60 billion. Latin America revenue fell 5.2% to $2.41 billion, but beat expectations of $2.29 billion, while Europe revenue rose 3.8% to $4.04 billion to top forecasts of $3.93 billion. "We ended the year on a strong note with our global beverage business having accelerated while our global snacks and food business remained resilient in the fourth quarter," said Chief Executive Ramon Laguarta. Separately, the company raised its annual dividend by 5%, to $4.30 a share from $4.09 a share, effective with the dividend to be paid in June. The stock has lost 4.3% over the past three months through Wednesday, while the S&P 500 has gained 9.4%.
9:22 a.m. Dec. 10, 2020 - By Ciara Linnane
U.S. sets record one-day death toll from coronavirus as FDA committee meets to review Pfizer–BioNTech vaccine FDA head says initial assessment is ‘this is a vaccine that does meet our criteria. ... But we do want to hear from the vaccine advisory committee.’The U.S. set fresh records for single-day fatalities from the coronavirus illness COVID-19 and hospitalizations, as a U.S. regulatory advisory committee gathered to offer its verdict on the vaccine developed by Pfizer Inc. and its German partner BioNTech SE.
9:26 a.m. Dec. 9, 2020 - By Ciara Linnane
U.S. coronavirus case tally climbs to 15 million from 14 million in just five days U.S. sets fresh record for COVID-19 hospitalizations; Angela Merkel pleads with Germans to limit gatherings during holidaysThe global case tally for the coronavirus illness COVID-19 climbed above 68 million on Wednesday and the U.S. tally rose above 15 million as the virus continued to race across the nation, filling hospitals with record numbers of patients
Browse topics:

Filter results by


Manufacturing (248)

Retail (205)

Financial Services (201)

Health-care (181)

Banks (179)

Food And Beverage (148)


Us (1248)

Europe (24)

Canada (17)

Asia Pacific (13)

China (10)

Eu (10)

Link to MarketWatch's Slice.